Erytech Pharma SA ADR

Company Profile

Erytech Pharma SA ADR had its IPO on 2016-07-05 under the ticker symbol ERYP.

The company operates in the Healthcare sector and Biotechnology industry. Erytech Pharma SA ADR has a staff strength of 49 employees.

Stock update

Shares of Erytech Pharma SA ADR opened at $0.91 at the start of the last trading session i.e. 2023-06-02.

The stocks traded within a range of $0.91 - $0.93, and closed at $0.92.

This is a +5.03% increase from the previous day's closing price.

A total volume of 1,855 shares were traded at the close of the day’s session.

In the last one week, shares of Erytech Pharma SA ADR have slipped by -8.2%.

Erytech Pharma SA ADR's Key Ratios

Erytech Pharma SA ADR has a market cap of $31.31 million, indicating a price to book ratio of 0.6542 and a price to sales ratio of 7.5782.

In the last 12-months Erytech Pharma SA ADR’s revenue was $6.65 million with a gross profit of $4.18 million and an EBITDA of $-24972000. The EBITDA ratio measures Erytech Pharma SA ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Erytech Pharma SA ADR’s operating margin was -408.41% while its return on assets stood at -30.14% with a return of equity of -0.98%.

In Q4, Erytech Pharma SA ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 571.5%.

Erytech Pharma SA ADR’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Erytech Pharma SA ADR’s profitability.

Erytech Pharma SA ADR stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 2.6278. Its price to sales ratio in the trailing 12-months stood at 7.5782.

Erytech Pharma SA ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$45.81 million

Total Liabilities

$11.68 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Erytech Pharma SA ADR ended 2023 with $45.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $45.81 million while shareholder equity stood at $23.49 million.

Erytech Pharma SA ADR ended 2023 with $0 in deferred long-term liabilities, $11.68 million in other current liabilities, 3102000.00 in common stock, $-228000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $38.79 million and cash and short-term investments were $38.83 million. The company’s total short-term debt was $3,340,000 while long-term debt stood at $7.55 million.

Erytech Pharma SA ADR’s total current assets stands at $42.63 million while long-term investments were $0 and short-term investments were $43000.00. Its net receivables were $2.53 million compared to accounts payable of $1.56 million and inventory worth $0.00.

In 2023, Erytech Pharma SA ADR's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Erytech Pharma SA ADR paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$0.92

52-Week High

$1.472

52-Week Low

$0.3

Analyst Target Price

$2.96

Erytech Pharma SA ADR stock is currently trading at $0.92 per share. It touched a 52-week high of $1.472 and a 52-week low of $1.472. Analysts tracking the stock have a 12-month average target price of $2.96.

Its 50-day moving average was $0.91 and 200-day moving average was $0.76 The short ratio stood at 0.23 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 765.2% are held by institutions.